Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma
Ross Firestone, Nicholas D. Socci, Tala Shekarkhand, et al.
Blood (2024) Vol. 144, Iss. 4, pp. 402-407
Open Access | Times Cited: 10

Showing 10 citing articles:

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
Luciano J. Costa, Rahul Banerjee, Hira Mian, et al.
Leukemia (2025)
Open Access | Times Cited: 3
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Tingting Yue, Yue Sun, Yun Dai, et al.
Blood Reviews (2025), pp. 101256-101256
Closed Access | Times Cited: 1
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Pralay Mukhopadhyay, Hesham Abdullah, Joanna Opalinska, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
Carlyn Tan, Sireesha Asoori, Chiung‐Yu Huang, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
Paola Neri, Noémie Leblay, Holly Lee, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 8, pp. 590-609
Closed Access | Times Cited: 7
GSI: myeloma—cold case closed?
Maximilian Merz, Nico Gagelmann
Blood (2025) Vol. 145, Iss. 2, pp. 148-149
Closed Access
The Interaction between the Bone Marrow Microenvironment and Immunotherapy in Multiple Myeloma: Mechanisms, Challenges, and Prospects
慧敏 张
Advances in Clinical Medicine (2025) Vol. 15, Iss. 04, pp. 1122-1130
Closed Access
Phase I Trial of MCARH109, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis
Eric M. Jurgens, Ross Firestone, Jagrutiben Chaudhari, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 2
Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: where do we stand today?
Xiang Zhou, K. Martin Kortuem, Leo Rasche, et al.
La Presse Médicale (2024), pp. 104265-104265
Open Access | Times Cited: 2
Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma
Nico Gagelmann, Maximilian Merz
Seminars in Hematology (2024) Vol. 61, Iss. 5, pp. 306-313
Open Access | Times Cited: 1
Page 1

Scroll to top